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Hepatoblastoma is the most common malignant liver tumour in
infants and young children. Its occurrence in the adult population
is debated and has been questioned. The aim of this paper is to
review the histological and clinical features of adult hepatoblas-
toma as described in the adult literature, and to compare the
ﬁndings with those of paediatric hepatoblastoma. The develop-
mental and molecular aspects of hepatoblastoma are reviewed
and their potential contribution to diagnosis of adult hepatoblas-
toma discussed.
Case reports of adult hepatoblastoma identiﬁed by a PubMed
search of the English, French, German, Italian, and Spanish liter-
ature through March 2011 were reviewed.
Forty-ﬁve cases of hepatoblastoma were collected. Age at pre-
sentation was variable. Survival was uniformly poor, except for
the rare patients who presented with the relatively differentiated,
foetal type. The common denominator between adult and paedi-
atric cases is the occurrence of embryonal or immature aspect of
the tumours. Whether the adult cases of hepatoblastoma repre-
sent blastemal tumours, stem cell tumours, or unusual differenti-
ation patterns in otherwise more frequent adult liver tumours
remains to be established. Adult tumours labelled as hepatoblas-
toma are characterised by malignant appearing mesenchymal
components. Surgical management is the cornerstone of therapy
in children and also appears to confer an improved prognosis in
adults.
Whether adult hepatoblastoma exists, remains controversial.
Indeed, several features described in adult cases are markedly
different from hepatoblastoma as it is understood in children,
and other differential diagnoses should also be entertained.
Nonetheless, hepatoblastoma should be considered in adults pre-
senting with primary liver tumours in the absence of pre-existing
liver disease. Adult and paediatric patients with immature hepa-
toblastoma appear to have worse outcomes, and adults present-Journal of Hepatology 20
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Hepatoblastoma (HB) accounts for approximately 1% of all paedi-
atric malignancies. Although rare, HB is the most common pri-
mary malignant hepatic tumour in children, with an annual
incidence of 0.5–1.5 per million in the paediatric population. A
majority of cases occur between the ages of 6 months and 3 years
[1,2]. Although HB has been reported in adults, its occurrence in
the adult population remains controversial. In the 2001 edition of
the Armed Forces Institute of Pathology (AFIP) on Tumours of the
Liver and Intrahepatic Bile Ducts, the authors declare that not one
adult HB case had been recorded at the AFIP [2]. They postulate
that the majority or all adult HB cases reported in the literature
(approximately 40 at that time) were actually misdiagnosed
hepatocellular carcinomas (HCC), combined HCC–cholangiocarci-
nomas, or carcinosarcomas. Even in paediatric malignant liver
cell tumours, clear-cut distinction between HB and HCC may
prove difﬁcult, since molecular, histological, and clinical ﬁndings
often overlap. These features are even more confusing in adults.
We discuss the similarities and differences between paediatric
and reported adult cases with respect to clinical presentation,
treatment, outcome, and pathological ﬁndings.
In addition, we review what is known about the developmen-
tal aspects, the molecular characteristics and regulation of the
different types of HB, how these relate to progenitor cells, and
how these tools might be of use in identifying adult HB. Finally,
we review surgical and medical management in children and
offer recommendations as to how these should be considered in
adults with HB features.Materials and methods
This paper by no means intends to be an exhaustive review of paediatric HB.
Instead, we review all 45 adult HB cases identiﬁed by a systematic PubMed search
of the English, French, German, Italian, and Spanish literature through March
2011. The data were compared and contrasted to internationally recognised HB12 vol. 56 j 1392–1403
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criteria. Finally, in order to better characterise the outcome of adult HB, survival
was assessed according to the Kaplan Meier method and group comparisons were
performed using the log-rank test. Standard alpha level of 0.05 indicated statisti-
cal signiﬁcance. Analyses were conducted using SPSS 15.0 (SPSS, Chicago, IL).Clinical ﬁndings
Paediatric HB
Most HB affect children below the age of 3 years, and the
median age at diagnosis is 1 year [3]. It classically arises
within a healthy liver, unaffected by underlying disease.
Children typically present with an asymptomatic abdominal
mass, and diagnosis is thus often made late, when disease is
already metastatic [4]. These tumours most commonly present
within the right lobe of the liver [5]. The lung is the most
frequent site for metastasis. Lymph node involvement is rare
[4]. On occasion, HB presents with intra-abdominal bleeding
secondary to a ruptured liver mass. Approximately 90% of
patients have highly elevated serum alpha-fetoprotein (AFP)
levels, which is both a sensitive diagnostic marker and a tool
to monitor response to therapy [6,7]. However, the most poorly
differentiated HBs (small cell undifferentiated for instance)
often have normal AFP levels and are associated with poorer
outcomes [6].
Adult HB
HB is rare in older children and exceedingly so in adults. The age
span of adult patients presenting with presumed HB was 17–
78 years (Fig. 1). Since 1958, 45 adult HB cases have been
reported in the literature [8–49]. An epidemiological survey of
fatal primary liver tumours in US residents less than 20 years of
age, between 1979 and 1996, disclosed four histologically proven
HB cases in the 15–19 year-old group [50]. These cases were not
included in Table 1 since the authors considered their survey as
paediatric.
Similar to what is seen in children, adult HB often presents
with a large liver mass. Adult HBs affect the right or left liver
lobes, and are very often uni-focal. AFP is often elevated, but
may be normal, as seen in children (elevated in 18/45 reported
cases, normal values in 8/45 cases, missing data in 19/45).
Lymph node metastases were observed in a few cases10 20 30 40 50 60 70 80 90
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Fig. 1. Age distribution of adult hepatoblastoma. No rule can be found
regarding age at manifestation.
Journal of Hepatology 2012[8,12,14,18,24,38], which is very atypical for HB as it is under-
stood in children. This observation raises two points: (1) Does
adult HB metastasize differently than what is understood in
children? (2) Were these tumours improperly classiﬁed as
HBs? Overall prognosis is poor, since most of the adult cases
died shortly after surgical and/or medical treatment.
Key Points 1 
Clinical  aspects of paediatric vs. adult hepatoblastoma
• Tumour characteristics:
- Number of nodules are similar in children and adults
- In children HB preferrentially affects the right lobe, in 
adults both lobes are equally affected
• Metastatic behaviour is different between the two age 
groups:
- Paediatric patients may display pulmonary 
metastases at diagnosis
- Adult patients may have lymph node and visceral 
metastases (including lung)Pathological ﬁndings in HB
Gross ﬁndings
Histology is central to the diagnosis of HB, but ﬁrst we will brieﬂy
review the gross characteristics.
Paediatric HB
The gross ﬁndings in the 35 HB case series reported by Ishak and
Glunz vary according to the subtype [51]. Half of the tumours
considered were encapsulated. A large majority showed a bulging
nodular or lobulated cut surface. In the mixed epithelial and mes-
enchymal HBs, a lobulated appearance is described, with inter-
vening white collagen bands, and areas of necrosis or
haemorrhage. The tumour nodules were variegated, tan to yellow
to greyish white, and a minority of cases showed bile-stained,
green nodules. Six of the 19 reported mixed HBs had prominent
vascular channels on the capsular or cut surface, and calciﬁca-
tions were noted in some of them. Most of the 16 epithelial
HBs were nodular, uniform and solid. They appeared greyish to
yellow or tan, with a minority displaying areas of haemorrhage
or necrosis.
According to the AFIP fascicle, pure foetal HB is characterised
by lobulated nodules whose colour often resembles normal liver
parenchyma. Mixed epithelial and mesenchymal HB shows a
more variegated appearance, with white and dense mesenchymal
areas alternating with brown or green epithelial nodules [2].
Osteoid may be grossly apparent. Areas of necrosis and haemor-
rhage may be seen in both cases.
Adult HB
The gross ﬁndings in the described adult HBs are not different
from those described in children. Some tumours are described
as encapsulated or surrounded by a pseudocapsule, whereas oth-
ers may display indistinct margins. The lesions are either single
or multiple, and are frequently described as variegated, with
areas of haemorrhage or necrosis. In mixed epithelial andvol. 56 j 1392–1403 1393
Table 1. Overview of the clinical ﬁndings of all published reports of cases recognised by the authors as adult hepatoblastoma (English, French, German, Italian, and
Spanish literature).
Year 
[Ref.]
Age 
(yr)
Size LS LD AFP Metastasis Medical 
treatment
Surgical 
treatment
Histological 
HB type
Follow-up Alive
1958 [8] 43 7 to 10 cm in Ø R + L + n.a. diaphragm, 
LN, lung
symptomatic - mixed, 
>mesenchymal
6 mo - 
1969 [9] 78 19 x 6 x 13 cm L - n.a. - - explorative 
laparotomy with biopsy
mixed 4 wk - 
1974 [10] 19 19 cm in Ø R n.a. no - - right hepatic lobectomy mixed n.a. n.a.
1976 [11] 34 10 x 12 cm R n.a. n.a. - - right lobectomy mixed n.a. n.a.
1978 [12] 51 12 x 10 x 10 cm R n.a. no LN  - - mixed death before 
surgery
- 
1979 [13] 60 1 to 6 cm in Ø R + L + ↑↑ portal vein, rib systemic 
chemotherapy
- mixed 2 mo - 
1980 [14] 72 large tumor R + n.a. LN, peritoneum, 
lung
symptomatic - mixed 2 wk - 
1980 [15] 27 25 cm R - n.a. lung - wedge biopsy of the 
tumor
mixed death 
immediately 
post-op.
- 
1981 [16] 73 9 x 8 x 8 cm 
and ++ small 
nodules
R + n.a. portal vein - laparotomy for biliary 
obstruction and biopsies
mixed, 
>mesenchymal
death 
immediately 
post-op.
- 
1982 [17] 68 large tumor R n.a. n.a. n.a. - resection mixed n.a. n.a.
1984 [18] 58 5 x 3 x 6 cm R n.a. n.a. LN - atypical right 
hepatectomy
epithelial 5 mo - 
1987 [19] 25 20 x 10 cm R n.a. n.a. n.a. - atypical resection after 
rupture
epithelial 2 wk - 
1987 [20] 53 15 cm in Ø R n.a. n.a. - - right hepatectomy mixed 1 yr + 
1989 [21] 22 7 x 6 x 6 cm L - ↑↑ pancreatic head chemotherapy left lobectomy + pancre-
aticoduodenectomy
epithelial 9 mo - 
1989 [22] 24 19 x 16 x 19 cm R n.a. n.a. - - right lobectomy mixed n.a. n.a.
1989 [23] 18 12 cm in Ø R n.a. ↑↑ ovaries systemic 
chemotherapy
resection of ovaries epithelial 9 mo - 
1990 [24] 66 1 to 12 cm in 
diameter
R + n.a. LN - - mixed 11 d - 
1990 [25] 82 7 cm at initial 
diagnosis
R + ↑ portal vein, from 
hepatic vein into 
atrium
arterial 
embolization, 
chemoembolization
- mixed 5 mo - 
1992 [26] 35 n.a. n.a. - n.a. n.a. n.a. n.a. epithelial (pure 
foetal)
n.a. n.a.
1992 [26] 73 18 x 18 x 10 cm R + n.a. n.a. n.a. n.a. mixed, 
>mesenchymal
n.a. n.a.
1994 [27] 25 1 to 20 cm in Ø R + L - no - - explorative laparotomy 
with only biopsy
epithelial 1 mo - 
1994 [27] 19 1 to 7 cm in Ø R + L - no lung - percutaneous biopsies 
→ hemorrhage
epithelial 1 d - 
1995 [28] 24 6 x 5 x 3 cm R - n.a. n.a. arterial 
embolization
extended right 
lobectomy
mixed 16 mo - 
1995 [29] 28 diffuse, 
involving liver + 
bile ducts
R + L + ↑↑ n.a. - palliative surgery mixed 4 wk - 
1995 [30] 22 14 cm in Ø n.a. - ↑ n.a. - extensive hepatectomy epithelial (pure 
foetal)
38 mo + 
1996 [31] 21 large tumor R - n.a. n.a. recurrences treated 
with chemo- and 
alcoholic 
embolizations, 
systemic 
chemotherapy
right trisegmentectomy epithelial 151 mo + 
1996 [31] 39 8 cm in Ø L + n.a. n.a. - liver resection and 
Billroth II
mixed 15 mo - 
1996 [32] 61 6 cm in Ø L - ↑↑ - arterial 
embolizations
left lobectomy mixed n.a. n.a.
1997 [33] 67 10 cm in Ø R - no - - resection of segments 
IV, V and VI 
mixed 2 wk - 
(continued on next page)
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Table 1. (continued).
Year 
[Ref.]
Age 
(yr)
Size LS LD AFP
x1000
Metastasis Medical 
treatment
Surgical 
treatment
Histological 
HB type
Follow-up Alive
1997 [34] 51 10 x 8 x 14 cm L + ↑↑ - - left lateral 
segmentectomy
mixed 2 mo - 
1997 [35] 44 18 x 13 cm n.a. - no direct extension 
to diaphragm 
- extended right 
hepatectomy
epithelial 5 mo - 
1999 [36] 27 1 to 10 cm in Ø R + L + ↑↑ lung systemic 
chemotherapy
- epithelial 1 mo - 
1999 [37] 47 1 to 2 cm in Ø R + L - 30,000 adrenal - - mixed some weeks - 
2001 [38] 23 15 x 12 x 9 cm L n.a. n.a. LN systemic 
chemotherapy
left lobectomy epithelial n.a.
2001 [39] 18 11 x 10 x 80 cm R + 1548,000 portal vein - right lobectomy mixed 12 mo + 
2004 [40] 20 4.5 to 18 cm 
in Ø
R + L - ↑↑ peritoneum arterial 
embolizations for 
tumor rupture
left trisegmentectomy 
including parts of the 
diaphragm
epithelial 2 mo -
2005 [41] 78 23 cm in Ø R + ↑↑ - - left lateral 
hepatectomy 
mixed 10 wk - 
2005 [42] 52 11 x 19 x 22 cm 
in the left lobe 
and 3 cm in 
segment VIII 
L + no - radiofrequency for 
right-sided lesion
left lateral 
hepatectomy 
epithelial 10 d n.a.
2006 [43] 19 14 cm in Ø R - no n.a. systemic 
chemotherapy
right trisegmentectomy mixed 6 mo - 
2007 [44] 34 1 x 11 x 9 cm R + ↑↑ - - right lobectomy mixed 3 mo - 
2007 [45] 17 multiple lesions 
involving both 
lobes
n.a. - ↑↑ - chemotherapy surgery epithelial n.a. n.a.
2009 [46] 54 3 and 6 cm in Ø R + ↑ - chemoembolization 
for recurrence
right lateral 
sectionectomy/right 
hepatectomy
mixed 31 mo + 
2010 [47] 25 25 x 15 x 18 cm n.a. - ↑↑ lung systemic 
chemotherapy and 
chemoembolization
left trisegmentectomy epithelial 4 yr n.a.
2010 [48] 30 23 x 14 x 13 cm R - ↑ - - right trisegmentectomy mixed n.a. n.a.
2011 [49] 33 19 x 15 x 14 cm L - ↑↑ direct extension 
to stomach; right 
lobe of the liver; 
lung
systemic 
chemotherapy and 
chemoembolization
left hepatectomy mixed 1 yr -
HB, hepatoblastoma; AFP, alpha-fetoprotein; no, normal; ", moderately elevated; "", highly elevated; LN, lymph nodes; n.a., not available, R, right; L, left; wk, weeks; mo;
months; yr, years; LS, liver side; LD, liver disease; Ø, diameter.
JOURNAL OF HEPATOLOGYmesenchymal HBs, osteoid, bone, and cartilage may be grossly
identiﬁed.
Histological criteria
Histological criteria of paediatric HB
The diagnosis of HB is mainly based on histology. In 1967, Ishak
and Glunz proposed two HB subtypes: (1) epithelial, (2) mixed
epithelial and mesenchymal. Prior to this description, HB may
have been unrecognised or labelled differently [51]. A more
aggressive macrotrabecular pattern, and the small cell undiffer-
entiated subtype were recognised later [52,53]. Not all of these
conventionally accepted characteristics are found in adult
lesions. In paediatrics, histology is commonly accepted to be of
prognostic value, and as such plays a central role in determining
therapeutic regimen.
Foetal and embryonal epithelial HB. The histological features of
epithelial HB consist of irregular lobules delineated by collagenJournal of Hepatology 2012septa of varying thickness [51]. The septa contain vessels, some
with a thick collagenous wall, and occasional lymphatics. The epi-
thelial cells are subdivided in ‘‘foetal-type and embryonal-type
cells’’ [2].
Foetal cells closely resemble the developing foetal liver, and
are arranged in irregular 2-cell thick plates (Fig. 2A). They are
smaller and more irregular than normal hepatocytes, with a mod-
erately abundant acidophilic cytoplasm, and a round to oval,
slightly irregular and basophilic nucleus. Pale cells, rich in glyco-
gen, alternate in a typical pattern with darker cells. Steatosis, and
intracytoplasmic or intracanalicular bile plugs may also be pres-
ent. Extramedullary haematopoiesis is frequent.
Embryonal cells appear far less differentiated: they are small,
elongated and poorly cohesive (Fig. 2B). They are arranged in
sheets or ribbons, focally organising into acinar or papillary struc-
tures, or pseudorosettes. Embryonal cells are dark cells, with
poorly deﬁned contours. Cytoplasm is scant and amphophilic.
The round to oval nucleus is hyperchromatic and contains a large
nucleolus. Mitoses are much more frequent in the embryonalvol. 56 j 1392–1403 1395
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Fig. 2. Histological features of different types of paediatric hepatoblastoma
(HB). (A) Foetal HB. Foetal cells resemble the developing foetal liver, and are
arranged in irregular 2-cell thick plates. A characteristic light and dark pattern is
imparted by variable cytoplasmic amounts of glycogen (haematoxylin & eosin
stain (H&E); original magniﬁcation 100). (B) Embryonal HB. Embryonal cells
appear less differentiated, small, elongated and poorly cohesive, forming pseud-
orosettes (H&E, 200). (C) Mixed (epithelial and mesenchymal) HB. In addition to
the epithelial elements (arrowheads), primitive mesenchyme consists of spindle–
shaped cells with plump elongated nuclei, in a parallel orientation (arrow) (H&E,
200).
Reviewareas than in the foetal-type areas. Unlike in the foetal type, the
embryonal type is characterised by the absence of glycogen, bile
pigment, or steatosis.
Mixed epithelial and mesenchymal HB and teratoid features. The
presence of mesodermal derivatives is characteristic of mixed,
epithelial and mesenchymal HB. (Fig. 2C) [51]. These mesenchy-
mal elements consist of a proliferation of primitive-appearing
mesenchymal spindle-shaped cells, intimately admixed with
the epithelial elements in a highly cellular pattern. Cytoplasm
is more abundant than that of mature ﬁbroblasts, and the nucleus
is elongated, and plump. These cells blend progressively with
areas of less intense cellular mesenchymal proliferation, and with
the relatively acellular, ﬁbrous septa. Osteoid is present in a
majority of cases, either within the primitive mesenchyme, near
the ﬁbrous septa or pseudocapsule, or admixed within the epi-
thelial elements. Osteoid foci contain cells morphologically iden-
tical to osteoblasts. Occasionally, squamous foci and a variety of
mesenchymal and epidermal derived tissues are visible, which
are considered teratoid elements [54,55]. Of note, neither carti-
lage nor rhabdomyoblasts were appreciated in the original
description by Ishak and Glunz [54].1396 Journal of Hepatology 2012Macrotrabecular pattern. Gonzalez-Crussi et al. further described
the more aggressive macrotrabecular pattern in HB, stressing
the difﬁculties of classifying such tumours as HB or HCC [52].
They argued however that other areas in such tumours displayed
a typical foetal pattern, thus lending support to a diagnosis of HB.
The ﬁve patients described all died with progressive disease,
some with unusual, skeletal metastases. The tumours displayed
10–20 or more cell thick trabeculae composed of foetal- or
embryonal-appearing cells admixed with occasional cells larger
than the normal uninvolved hepatocytes and anaplastic cells. In
addition, there was marked vascular invasion within the tumours
[52].
Small cell undifferentiated HB. The ﬁnal HB subtype described in
children is the small-cell undifferentiated pattern (SCU) previ-
ously called ‘‘anaplastic’’ [53]. This pattern is characterised by
small, undifferentiated and poorly cohesive cells, with scant cyto-
plasm and hyperchromatic nuclei, initially described as ‘‘resem-
bling neuroblastoma cells’’ [13]. Since 1989, small cell
undifferentiated HB is the term used to describe tumours pre-
senting with more than 50% of small-cell undifferentiated areas
[56]. High mitotic rates and a possible primitive spindle cell com-
ponent were reported in these tumours [56]. Some cases were
associated with a foetal or an embryonal pattern [57].
Correlation between histology and outcome. Only HBs displaying a
pure foetal histology and a low mitotic rate (<2 mitoses/10 high
power ﬁelds, 400) are deﬁned as favourable histology, and have
better survival [56]. All other subtypes are deﬁned as unfavour-
able histology; in particular, SCU histology is associated with an
adverse outcome [57].
In children with incompletely resected HB or with metastasis
at initial diagnosis, identiﬁcation of osteoid or chondroid foci, or
of squamous differentiation has been associated with increased
survival [56]. However, these elements had no inﬂuence on prog-
nosis in completely resected HB. Since paediatric HBs with mes-
enchymal components have not been shown to behave more
aggressively than other subtypes, they are not mistaken for sar-
comas, unlike what might be a challenge in adult cases [52].
Histological criteria of adult HB
Whether HB exists in adults is controversial. As previously men-
tioned, most or all adult cases published were deemed misdiag-
nosed by the authors of the 2001 edition of the AFIP on
Tumours of the Liver and Intrahepatic Bile Ducts [2]. We have
not personally been confronted to adult cases of HB. This section
will thus mostly be dedicated to a summary of the main ﬁndings
in published adult HB cases, and to a discussion of the potential
differential diagnoses in adults.
Underlying ﬁbrosis or cirrhosis was identiﬁed in 11 of the 45
published HB adult cases [14,16,24–26,34,37,41,46,58]. An addi-
tional ﬁve patients had a history of viral hepatitis (A, B or C),
but no reported ﬁbrosis [13,31,36,39,42]. In contrast, childhood
HB occurs almost always in patients with no underlying liver dis-
ease [59].
In adult HB, authors often underscore the malignant appear-
ance of mesenchymal elements. Such areas are described as
reminiscent of ﬁbrosarcoma, osteosarcoma, chondrosarcoma,
angiosarcoma, or rhabdomyosarcoma [9,13–15,17,24,26,32,34,
41,49]. The latter deserves particular mention, since rhabdomyo-
blasts were not observed in the two large paediatric seriesvol. 56 j 1392–1403
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[52,53], although they were described sporadically in another ser-
ies [60]. Identiﬁcation of rhabdomyoblastic differentiation should
therefore prompt careful evaluation of all tumour features, and
consideration of differential diagnoses, such as teratoma [52]. Con-
versely, small undifferentiated cells are not pathognomonic of HB.
For example, scattered clusters of highly undifferentiated oval or
round cells, with scant cytoplasm in the epithelial component of
a rhabdomyosarcoma-like liver tumour,were not considered diag-
nostic of HB in a 70-year old patient [61].
Differential diagnosis of adult HB
Hepatocellular carcinoma, and combined hepatocellular–
cholangiocarcinoma with stem cell features
The main differential diagnosis of HB is HCC. The challenge is to
distinguish HB from HCC which often show signiﬁcant gross and
histological overlap. Both tumours can present with a macrotrab-
ecular pattern or poorly differentiated characteristics. Moreover,
immunohistochemistry is of limited value in distinguishing
between HCC and HB. To further complicate matters, both mixed
HB and HCC features can exist within a same tumour [62]. Fur-
thermore, the sequential development of HB and HCC in the same
patient has been reported [46,63]. Finally, chemotherapy may
result in cytologic and architectural modiﬁcations that mimic
HCC, with resulting increases in both tumour cell size and nuclearTable 2. Histological clues and criteria distinguishing hepatoblastoma (HB) from
architectural and morphological overlap; unambiguous distinction may prove difﬁcult, es
variants with major overlapping features described. Histologic HCC variants (ﬁbrolamella
N/C ratio, nuclear/cytoplasmic ratio; HPF, high power ﬁeld.
Hepatoblastoma
Histological clues • “Light and dark” pattern
• Extramedullary hematopoiesis
• Mesenchymally-derived tissue
Foetal type HB Embryonal type HB
Architecture Cords or thin plates, 
intervening sinusoids
Dense sheets, roset
Tumour cell 
trabeculae
Thinner - 
Tumour cell size Smaller cell size Small cells
Cell characteristics Uniform small cuboidal 
cells resembling foetal liver
Irregular, angulated 
resembling embryon
Distinct cell membrane Indistinct cell membr
Uniform nuclei Mild nuclear anisocy
and hyperchromasia
Abundant clear, granular or 
smooth cytoplasm
Scant, more basoph
cytoplasm
Low N/C ratio High N/C ratio
Mitoses Low mitotic rate Frequent; bizarre mi
uncommon
Journal of Hepatology 2012anaplasia [64]. When present, mesenchymal elements are a key
feature of paediatric HB. In contrast, in adult liver tumours, the
presence of spindle-cells is not conclusive, since they can also
be seen in HCC and in sarcomatous liver tumours. Table 2 sum-
marises the main histological criteria to distinguish HB from
HCC. Extramedullary haematopoiesis is a useful criterion in the
diagnosis of HB, but may also be observed in a small subset
(5%) of HCC cases. Bile production is more rarely seen in HB than
in HCC [2]. Paediatric HB rarely occurs in the setting of underly-
ing liver disease while 25% (11/45) of published HB adult cases
showed underlying ﬁbrosis or cirrhosis [13,14,16,24–
26,34,37,41,46].
Patients with combined hepatocellular–cholangiocarcinoma
are thought to have worse clinical outcome than patients with
pure HCC [65]. Some tumours further display stem cell features,
with clusters of small cells with high nucleocytoplasmic ratio,
and hyperchromatic nuclei. The immunophenotype recapitulates
that of stem or progenitor cells, with reactivity to the progenitor
cell/ductular markers cytokeratins 7 and 19, neural cell adhesion
molecule (NCAM1/CD56), KIT (CD117), epithelial cell adhesion
molecule (EpCAM), and the hepatic progenitor cell marker OV–
6 [44,66–68]. It remains to be determined to what extent these
features observed in patients with conﬂicting clinical outcome
relate to the poorly or undifferentiated aspects described in some
of the adult HBs.classical hepatocellular carcinoma (HCC). HB and HCC may show signiﬁcant
pecially in particular HB variants. Histological clues to diagnosis are provided and
r HCC, clear cell carcinoma, sarcomatoid HCC, sclerosing HCC) are not considered.
Hepatocellular carcinoma (classical HCC)
• Underlying cirrhosis
• Cytoplasmic inclusions, bile production
• Bizarre nuclei, giant tumour cells
HCC (classical HCC) HB-HCC 
overlapping patterns
tes Trabecular, acinar, 
scirrhous patterns
Trabecular architecture in
macrotrabecular HB
Larger Large 10-20 cell-thick
trabeculae in 
macrotrabecular HB
Cells larger than normal 
hepatocytes
Small undifferentiated cells
(SCU HB vs. undifferentiated
characteristics in HCC)
cells, 
al liver
Large polygonal cells 
(varies with tumour grade)
“HCC-like” cells in 
macrotrabecular HB
ane Distinct cell membrane
tosis Nuclear anisocytosis,
hyperchromasia (vary with
tumour grade)
ilic Moderate amounts of 
eosinophilic cytoplasm
Variable N/C ratio 
according to tumour grade
toses Frequent; bizarre mitoses Higher mitotic activity in
mitotically-active foetal HB
(>2 mitoses/10 HPF)
vol. 56 j 1392–1403 1397
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Ossifying stromal–epithelial tumour/(calcifying) nested stromal
epithelial tumour of the liver
Another important differential diagnosis is the rare, ossifying
stromal–epithelial tumour. The three initial cases reported as
ossifying stromal–epithelial tumours in the AFIP fascicle had
been present since childhood, as a calciﬁed liver mass [2].
Nomenclature is confusing: these rare tumours have also been
called ossifying malignant mixed epithelial and stromal tumours
of the liver [69], nested stromal epithelial tumours of the liver
[70], desmoplastic nested spindle cell tumours of the liver [71],
and calcifying nested stromal epithelial tumours of the liver
[72]. Age range at presentation varies from 2 to 14 years [70],
while age at the time of diagnosis is 2–33 years [72]. Tumours
consist of mixed epithelial and stromal elements arranged in
spindle and epithelioid cellular nests, surrounded by a concentric
myoﬁbroblastic proliferation. The stroma contains variable
amounts of calciﬁcations, osteoid, and bone [70,72]. The main dif-
ference with HB is immunohistochemistry: this rare tumour does
not stain for HepPar1, AFP, and cytokeratin 7, whereas WT–1
reactivity is observed [70,72].
Transitional liver cell tumours
There is one report of aggressive malignant liver cell tumours dis-
playing morphological aspects intermediate between HB and HCC
which were labelled as transitional liver cell tumours (TLCT) [73].
This is a clinically relevant paediatric series because some of
these tumours were identiﬁed as HB on pre-treatment diagnostic
biopsy, whereas the post-treatment liver specimen displayed fea-
tures more in keeping with HCC. Recently, as previously stressed,
phenotypic modiﬁcations have been reported in post-treatment
HB [64], with cellular maturation or modiﬁcation to a HCC-like
phenotype. Together, these reports highlight the difﬁculties in
distinguishing between the two entities and should be consid-
ered in clinical management.
Recent molecular advances have allowed identiﬁcation of dif-
ferent patterns of gene expression [74], and distinguishing
between HB and HCC might soon rely on molecular techniques.
Key Points 2 
Morphological aspects of paediatric vs. adult hepatoblastoma
• 
• Histological differences between adult and pediatric HB 
include:
- 
either represent a true difference between paediatric 
and adult cases, or identify cases belonging to other 
categories
- Osteoid, chondroid and teratoid elements may be 
favourable prognostic factors in children, in particular 
settings
- Small cell undifferentiated HB is recognized in a 
subset of pediatric HB, but has not been reported in 
cells in liver tumours is not diagnostic of HB
• Embryonal or undifferentiated cells indicate poor outcome 
in all adult liver tumours
Gross findings are similar in paediatric and adult HB, but
are not specific
Sarcomatoid elements in adult HB. This finding may
adults. Identification of embryonal/undifferentiated1398 Journal of Hepatology 2012Developmental and molecular aspects of HB
Early descriptions of HB highlighted its histological resemblance
to the hepatoblast, commonly accepted as the bipotential precur-
sor of both the hepatocyte and cholangiocyte lineages [51]. AFP
expression by the tumour attests the expression of a ‘foetal’ pro-
gramme. With the advent of molecular methods, a progenitor-
cell origin has been convincingly demonstrated for HCC, joining
the vast body of literature in support of a cancer stem cell
hypothesis [75–77]. Several elements support a similar origin
for HB: onset in infancy and childhood, association with genetic
syndromes favouring overgrowth and tumour development
[78–80], and frequent absence of underlying liver disease. In
addition, histological subtypes appear to recapitulate foetal
development to some extent and may include teratoid elements
[81], suggesting a pluripotency of the tumour, or at the very least,
the creation of a permissive environment for diverse cellular dif-
ferentiation within the tumour itself. Finally, and perhaps most
convincing, is the ﬁnding that the bipotential oval cell marker
DLK1 has been shown to be upregulated in HB [82].
Several investigators have indeed used gene expression anal-
ysis to identify molecular signatures between subtypes. The dif-
ferent histological subtypes described above (foetal vs.
embryonal, epithelial vs.mesenchymal, and small cell undifferen-
tiated) offer an attractive avenue to explore genotype–phenotype
correlations and possible embryonic origins. The common
denominator of most of these studies has been the use of the foe-
tal liver (usually murine) as a reference for liver development
[83,84]. Most recently, Buendia and colleagues used a combina-
tion of gene expression proﬁles and array comparative genomic
hybridization (CGH) analysis to show that foetal and embryonal
subtypes mirror the molecular signature of early or late liver
development [83]. This important study conﬁrms a genetic and
molecular origin to the long standing assumption that the more
immature, embryonal phenotype leads to a more aggressive dis-
ease than the foetal type, commonly accepted as a sign of favour-
able outcomes [83].
Furthermore and most relevant to this review, a recent analy-
sis using gene proﬁling of different adult HCCs showed that a
subset of tumours clustered with mouse hepatoblasts around
embryonic day 13–16 [75]. The subset of patients having this
type had worse outcomes than non hepatoblast-like HCCs [75].
Taken together, these last two observations beg the question
whether these tumours with molecular, foetal characteristics
were not in fact adult HBs which might have warranted a differ-
ent management than conventional HCC therapy.
The possibility of molecular overlap between HCC and HB is
important when approaching an atypical adult hepatic epithelial
tumour. Mixed HB and HCC phenotypes have been described
within the same tumour [62], and the presence of both tumour
types has been described in patients either in a synchronous or
sequential fashion [46,63]. There can be signiﬁcant histological
resemblance between HB and HCC. Furthermore, as many as
28% of HCCs in one series stained positively for CK7 and/or
CK19, compatible with a progenitor-cell origin. Interestingly,
these CK19 positive tumours had a worse prognosis [85]. Addi-
tionally, developmental signalling pathways such as Wnt, Hh,
and Notch which have all been shown to be important in HB
pathogenesis [44,62,86–88], also play a more or less important
role in the development and maintenance of HCC, which suggestsvol. 56 j 1392–1403
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that there is at least some overlap in oncogenic programmes in
these two tumours [86,89–91].
While it is tempting to consider that HB and HCC may share a
common progenitor, this is far from clear. Indeed, the adult liver
appears to contain multiple progenitor candidates ([92],
reviewed in [88]) and it is true that chronic liver disease gives rise
to HCC. The big difference between HCC and HB is that HB arises
most often in a normal liver. Therefore, it is unclear whether
indeed the same progenitor cell is at play. However, one might
postulate that at least in some cases, there may be an overlap
in the origin of the two tumours.
Key Points 3 
Developmental aspects of hepatoblastoma and hepatocellular
carcinoma
• Detailed molecular studies suggest that HB may derive 
from progenitor cells, akin to what is commonly accepted 
now for solid tumours, including HCC
• Molecular overlap and co-existence of HB and HCC 
in paediatric and adult patients support the emerging 
hypothesis that these two tumours may derive from a 
common progenitor cell
• Advances in the genetics of HB seem to support the 
long-standing hypothesis that its pathobiology in part 
recapitulates liver development
• Future studies will help
- elucidate the molecular biology governing cell fate 
decisions thereby identifying potential therapeutic 
targets.
- differentiate between HCC and HBII
III
IV
Fig. 3. PRETEXT (pre–treatment tumour extension) staging system (www.sio-
pel.org). PRETEXT reﬂects the number of liver sections, which are free – or
involved – of tumour: PRETEXT I: three adjoining liver sections free, one section
involved; PRETEXT II: two adjoining sections free, two sections involved;
PRETEXT III: two non-adjoining sections free or just one section free, in the
latter case three sections involved; PRETEXT IV: no free section, all four sections
involved.Therapeutic protocols and outcome
Therapy and outcome in paediatric HB
Overview
The International Childhood Liver Tumour Strategy Group (SIO-
PEL), a committee of medical specialists founded in 1988 under
the umbrella of the International Society of Paediatric Oncology
(SIOP), promotes basic and comprehensive clinical research on
childhood malignant neoplasms of the liver, mainly HB and
HCC. The ultimate goal of this study group is to ameliorate the
prognosis and the quality of life of children affected by these rare
neoplasms and to promote international cooperation
(www.siopel.org).
Worldwide, there are two different strategies regarding the
treatment of paediatric HB. The North American groups support
immediate surgery for localised tumours [93,94], whereas Europe
favours pre-operative chemotherapy in all cases, followed by sur-
gery. In most cases and depending on risk factors and staging,
post-operative chemotherapy is also recommended. In the fol-
lowing paragraphs, we summarise the current European strategy
of risk-adapted therapy, as outlined by SIOPEL following Euro-
pean-wide research.Journal of Hepatology 2012The prognosis for HB has dramatically improved since the
introduction of effective, cisplatin-based chemotherapy in the
1980’s. Five-year overall survival has improved from 25% to
around 70% [95]. Alternating cycles of cisplatin, doxorubicin
and even carboplatin are administered based on the risk-groups
of HB patients (histological type, tumour extension, AFP secre-
tion, etc.). The SIOPEL group is currently investigating the efﬁcacy
of a high-dose cisplatin regimen in high-risk patients and the efﬁ-
cacy of irinotecan in patients with recurrent disease [96]. These
approaches might be part of future therapeutic strategies against
advanced HB (www.siopel.org).
The SIOPEL established the PRETEXT (pre-treatment tumour
extension) staging system, reﬂecting the number of liver sections
with or without tumour (Fig. 3). The aim of the PRETEXT classiﬁ-
cation is to assess the feasibility of complete tumour resection
prior to any treatment. This approach has shown reliable inter-
observer reproducibility and an excellent prognostic value
[97,98]. Its main limitation is the difﬁculty to distinguish
between actual invasion of a liver segment or displacement of
an anatomical border. This may lead to over-staging [99]. The
SIOPEL studies have identiﬁed factors associated with lower sur-
vival in patients with HB: (1) tumour involving all four hepaticvol. 56 j 1392–1403 1399
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Fig. 4. Survival of adult hepatoblastoma patients. (A) Overall survival of adult
hepatoblastoma patients (n = 34). Median survival: 2 months (95% CI 0.09–3.91).
One-year survival: 24%. (B) Survival of hepatoblastoma patients younger than and
older than 45 years. One-year survival: 42 ± 13% if age 645 (n = 17), 0% if age >45
(p 60.004, n = 17). (C) Survival of surgically treated patients with adult hepato-
blastoma. One-year survival: 41 ± 12% in patients with resection (n = 17), 0% in
those with palliative management (p 60.001, n = 16). (D) Survival of adult
patients with reported hepatoblastoma before and after 1995. Patients treated
after 1995 show a better survival curve (p = 0.018, n = 17 in both groups).
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sections (Fig. 3), (2) presence of distant metastasis, (3) tumour
extension into the vena cava, all three hepatic veins or the main
and/or both branches of the portal vein, (4) biopsy-proven extra-
hepatic intra-abdominal disease, (5) low serum AFP (<100 ng/ml),
(6) tumour rupture at presentation [6,96]. Meyers et al. further
exposed a histological factor to be prognostic: small undifferenti-
ated histology showed to have worse prognosis [100].
Surgical strategies for paediatric HB
In Europe, surgery is usually performed after pre-operative che-
motherapy. Complete tumour resection is the crucial step in cur-
ing HB [101]. Radical tumour resection can be achieved either by
conventional hepatic surgery or orthotopic liver transplantation.
As a general rule, PRETEXT I–III tumours are treated with partial
hepatectomy, and PRETEXT IV or unifocal, centrally-located
tumours with total hepatectomy, i.e. liver transplantation [101].
Large solitary PRETEXT IV HBs can be an exception to this
principle as a local resection can become feasible after success-
ful downstaging with pre-operative chemotherapy (thus avoid-
ing liver transplantation). This may be the case when the
anatomical border of a liver sector is compressed without true
malignant invasion. On the other hand, unifocal, centrally-
located HBs are more likely to be treated by liver transplanta-
tion when they involve the main hilar structures or main hepa-
tic veins, as these structures would presumably not become
tumour-free even after a good response to chemotherapy.
Indeed, initial invasion of the portal or hepatic veins is not a
deﬁnite contraindication to liver transplantation [102,103].
Yet, a review including the worldwide experience with HB
has shown that such venous invasions are associated with sig-
niﬁcantly lower survival after liver transplantation: long-term
survival was 54% if macroscopic venous invasion was present
vs. 78% if there was no invasion [95].
Of note, children with multifocal PRETEXT IV tumours in
whom tumour nodules respond to pre-operative chemotherapy
should also beneﬁt from primary liver transplantation (provided
that all lesions cannot be removed by partial liver resections).
This principle is guided by the high risk of recurrence from small
non-detected viable HB cell remnant after chemotherapy. The
sites of all currently and previously visible HB lesions should be
excised [104].
Lung metastases are not an absolute contraindication to liver
resection or even liver transplantation. All pulmonary metastases
should be removed ﬁrst (wedge resection with wide margins)
and the primary tumour subsequently resected – either by partial
hepatectomy or by liver transplantation [105]. Some data even
support that liver transplantation is a reasonable option if lung
metastases have been eradicated by chemotherapy [95].
The rare absolute contraindications to liver transplantation
are (1) the persistence of one or more viable extrahepatic tumour
deposits not amenable to surgical excision; and (2) non-response
to pre-operative chemotherapy, because of the high likelihood of
systemic dissemination of the tumour [95].
In selected patients with HB, special hepatic resection tech-
niques may be used by experienced liver surgeons [106].
Exceptionally, if the tumour is adjacent to major vessels, they
may be resected and reconstructed. Similarly, pre-operative
hepatic artery chemoembolization may be considered [107].
Even tumour encasement or ingrowth into the retrohepatic
vena cava may not preclude a radical excision, since the vein
can be resected en bloc and replaced under total vascular1400 Journal of Hepatology 2012exclusion of the liver (which usually is very well tolerated by
children) [108,109]. Yet, difﬁcult resections should be avoided.
They carry a high probability of leaving residual tumour, espe-
cially with tumours adherent to major hepatic vessels. The sig-
niﬁcantly better survival rates obtained in patients who
received a primary transplant after a good response to chemo-
therapy support the strategy of avoiding partial hepatectomies
when radical resections seem difﬁcult and unlikely. Excellent
results have been reported with primary liver transplantation
compared to those obtained by rescue transplantation: 6-year
survival after primary transplantation has been shown to be
82% vs. 30% for patients with rescue transplantation after
primary partial liver resection [95]. Consequently, whenvol. 56 j 1392–1403
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intra-hepatic recurrence is observed after a previous partial
hepatectomy, the indication for rescue liver transplant remains
controversial.
Therapy and outcome in adult HB
Based on the review of the literature, it is clear that there is no
standardised management of adult HB. In all cases, surgery was
the ﬁrst-line approach, but pre-operative chemotherapy was
not administered. Radical surgical excision appears to be the
‘‘gold standard’’. Based on paediatric experience, we suggest
treating adults in the same way as children: start treatment with
cisplatin-based pre-operative chemotherapy, followed by sur-
gery. Multicentre efforts should focus on implementing standard-
ised guidelines.
Outcome of adult HB is poor. Overall median survival in the
reviewed adult population was 2 months (95% CI 0.09–3.91), 1-
year survival being 24% (Fig. 4A). Similar to children, adult
patients with foetal HB may have better survivals. However, only
two such cases have been reported (only one including outcome
data) and no meaningful statistical analysis could be conducted
with this subgroup of HB. Younger patients demonstrated signif-
icantly better survivals (1-year survival: 42 ± 13% if age 645 and
0% if age >45, p = 0.004, Fig. 4B). Patients undergoing liver resec-
tion demonstrated improved survivals compared to those with
biopsy and/or palliative treatment. One-year survival was
41 ± 12% in patients with resection and 0% in those with pallia-
tive management (p 60.001, Fig. 4C). Chemotherapy had no
impact on outcome. Patients reported since 1995 demonstrated
better survivals than those reported prior to 1995, suggesting
an improvement in the management of HB in adults (p = 0.018,
Fig. 4D). Upon analysis of risk factors of the reported adult HB
cases, the following variables did not impact on outcome: AFP-
secretion (p = 0.34), size of largest tumour (p = 0.81) (univariate
Cox analysis), as well as presence of metastasis (p = 0.51) (Kaplan
Meier analysis).
Key Points 4 
Suggested treatment strategies for paediatric vs. adult 
hepatoblastoma
• Application of paediatric HB protocols in adult HB may 
• Surgery is the cornerstone of pediatric HB management 
and should be considered in adults
• Complete resection is mandatory
prove beneficialConclusions
Whether adult hepatoblastoma exists, remains controversial
since many features of published cases are not found in paedi-
atric HB and vice versa, and differential diagnoses were felt to
be possible. However, the diagnosis of HB should be considered
in adults presenting with primary liver tumours in the absence
of pre-existing liver disease. Patients with immature tumour
characteristics have a poor prognosis. In all patients, surgery
should be the treatment of choice, neoadjuvant chemotherapyJournal of Hepatology 2012is advisable. Collaborative efforts are necessary to conﬁrm the
existence of adult HB and further characterise these rare
tumours. Molecular tools may soon help in making this diagno-
sis. Multicentre efforts will help in designing standardised
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